PELNSEPiramal Enterprises Limited· PharmaceuticalsMediumNeutral
Announced Mon, 2 Jun · 14:31 IST

Piramal Enterprises Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsInvestor Communications View source PDF
Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Piramal Enterprises shared its Q4 & FY25 results and FY26 outlook at the Nomura Investment Forum in Singapore. Consolidated AUM grew 17% YoY to INR 80,689 Cr, with the retail-to-wholesale mix improving to 80:20 from 70:30. The company swung to a consolidated profit of INR 485 Cr in FY25 from a loss of INR 1,684 Cr in FY24, helped by AIF gains of INR 926 Cr and a sharp drop in provisions. All FY25 targets were met, including legacy AUM reduction to INR 6,920 Cr (9% of total) and opex-to-AUM falling to 4.0%. Key updates include RBI approval for the PEL-Piramal Finance merger (expected by Sep 2025) and the conversion of Piramal Finance from an HFC to an upper-layer NBFC. FY26 guidance targets ~25% AUM growth to ~INR 100,000 Cr and consolidated PAT of INR 1,300–1,500 Cr.

Likely market impact

Strong FY25 results, achievement of all guided targets, and a clear FY26 growth roadmap with sharply higher profit guidance are positive signals for shareholders. The pending PEL-PFL merger should simplify the group structure and provide direct lending business exposure, though investors should watch legacy book runoff and merger execution timelines.